The role of lymphadenectomy in high risk prostate cancer

World Journal of Urology

Volumn 26, Issue 3, 2008, Pages 231-236

  Burkhard, Fiona C ^a   Studer, Urs E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

High risk prostate cancer; Lymphadenectomy; Nodal metastases; Radical prostatectomy

Indexed keywords

ARTICLE; CANCER STAGING; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METASTASIS; METHODOLOGY; MORTALITY; PROSTATE TUMOR; PROSTATECTOMY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 44649137934     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0251-6     Document Type: Article

References (41)

1. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 32:385-390
2. Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW (2004) Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 172:1835-1839
3. Lerner SE, Blute ML, Zincke H (1995) Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: Outcome and contemporary morbidity. J Urol 154:1447-1452
4. van den Ouden D, Hop WC, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392-1397
5. Messing E, Manola J, Sarosdy M, Wilding G, Crawford D, Trump D (2003) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer; results at 10 years of EST 3886. J Urol 169:396
6. D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW (2000) Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. Jama 284:1280-1283
7. Scardino P (2005) Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3(Suppl 1):S29-S33
8. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106-2131
9. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J Urol 178:493-499 (discussion 499)
10. D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:56-61
11. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-1527
12. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ (2007) Prostate-specific antigen velocity risk count assessment: A new concept for detection of life-threatening prostate cancer during window of curability. Urology 70:685-690
13. Bader P, Spahn M, Huber R, Echtle D, Frohneberg D (2004) Limited lymph node dissection in prostate cancer may miss lymph node metastasis and determines outcome of apparently pN0 prostate cancer. Eur Urol 3:16 (A 55)
14. Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121-125
15. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98:788-793
16. Mattei A, Fuechsel FG, Dhar NB, Warncke SH, Thalmann GN, Krause T, Studer UE (2007) The template of the primary lymphatic landing sites of the prostate should be revisited: Results of a multimodality mapping study. Eur Urol 53:118-125
17. Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G, Poulsen J (2003) Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Scand J Urol Nephrol 37:382-386
18. Cabanas RM (1977) An approach for the treatment of penile carcinoma. Cancer 39:456-466
19. Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166:1715-1719
20. Bader P, Burkhard FC, Markwalder R, Studer UE (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514-518 (discussion 518)
21. Heidenreich A, Varga Z, Olbert P, Hofmann R (2001) Radical pelvic lymphadenectomy in clinically localised prostate cancer: High frequency of atypical metastasis. Eur Urol 39(suppl. 5):135 (A 530)
22. Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M (2004) Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 171:2268-2271
23. Mattei A, Fuechsel FG, Warncke S, Z'Brun S, Baermann C, Krause TM, Studer UE (2005) Advantages of preoperative imaging with Technetium-99m-nanocolloid for prostate-sentinel-lymph-node-adenectomy: accuracy and surgical detection time using presurgical imaging guidance prior to gamma-probe-detection versus gamma-probe detection alone. J Urol 173:433
24. Gronau E, Weckermann D, Harzmann R (2005) Sentinel lymph node resection in prostate cancer patients with a PSA higher than 20 ng/ml. J Urol 173:437
25. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491-2499
26. Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis. J Urol 167:1681-1686
27. Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Markl B, Gordijn R, Harzmann R (2003) The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43:132-137
28. Stone NN, Stock RG, Unger P (1997) Laparoscopic pelvic lymph node dissection for prostate cancer: Comparison of the extended and modified techniques. J Urol 158:1891-1894
29. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N, Smith JA Jr (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145-147 (discussion 147-148)
30. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173:1121-1125
31. Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA, Scardino PT (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175:1320-1324 (discussion 1324-1325)
32. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M et al (2006) Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24:3081-3088
33. Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M (2007) Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13:1192-1197
34. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ (2006) Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735-2742
35. Golimbu M, Morales P, Al-Askari S, Brown J (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617-620
36. Catalona WJ, Miller DR, Kavoussi LR (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 140:540-543
37. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. Jama 281:1591-1597
38. Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849-854
39. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864-870 (discussion 870-861)
40. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 172:2252-2255
41. Campbell SC, Klein EA, Levin HS, Piedmonte MR (1995) Open pelvic lymph node dissection for prostate cancer: A reassessment. Urology 46:352-355